Document Detail

Lone atrial fibrillation: where are we now?
MedLine Citation:
PMID:  22056820     Owner:  NLM     Status:  MEDLINE    
There is a growing pandemic of atrial fibrillation (AF), affecting nearly 2% of the general adult population. Atrial fibrillation is commonly associated with structural heart disease, and AF itself causes a sequence of complex processes of electrical, contractile, and structural remodeling of the atrial myocardium, which facilitate further AF progression. Nonetheless, AF may also affect individuals aged ≤ 65 years who have no evidence of associated cardiopulmonary or other disease, including hypertension; this is otherwise referred to as "lone" AF and is considered to have a generally favorable prognosis. The true prevalence of lone AF is unknown. Growing insights into the diversity of numerous mechanisms involved in the pathogenesis of AF, including acute atrial stretch, structural and electrophysiological alterations, systemic inflammation, oxidative stress, autonomic imbalance, genetic predisposition, and many others, and increasing recognition of novel risk factors for AF, including obesity, metabolic syndrome, subclinical atherosclerosis, sleep apnea, alcohol consumption, and endurance sports, suggest that apparently lone AF might not be so "lone" in many patients, which could have important prognostic and therapeutic implications. In this article, we summarize the current knowledge of epidemiology, etiopathogenesis, and pathophysiology of so-called lone AF and discuss the issues of long-term prognosis and management of patients who have an apparently lone AF.
Tatjana S Potpara; Gregory Y Lip
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Hospital practice (1995)     Volume:  39     ISSN:  2154-8331     ISO Abbreviation:  Hosp Pract (1995)     Publication Date:  2011 Oct 
Date Detail:
Created Date:  2011-11-07     Completed Date:  2012-01-26     Revised Date:  2013-04-10    
Medline Journal Info:
Nlm Unique ID:  101268948     Medline TA:  Hosp Pract (1995)     Country:  United States    
Other Details:
Languages:  eng     Pagination:  17-31     Citation Subset:  AIM; IM    
Cardiology Clinic, Clinical Center of Serbia, Belgrade, Serbia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Atrial Fibrillation* / epidemiology,  etiology,  physiopathology,  therapy
Biological Markers / analysis
Clinical Trials as Topic
Disease Progression
Risk Factors
Reg. No./Substance:
0/Biological Markers

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Apixaban for stroke prevention in atrial fibrillation: a review of the clinical trial evidence.
Next Document:  Duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting ste...